Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

BMS' Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

Lymphoma is a ... and/or refractory large B cell lymphoma, and these therapies are increasingly being administered as earlier-line therapies. Nonetheless, the prognosis of these patients is ...

Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...